Influenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Influenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2023’, provides an overview of the Influenza A Virus, H1N1 Subtype Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections
- The report reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Influenza A Virus, H1N1 Subtype Infections therapeutics and enlists all their major and minor projects
- The report assesses Influenza A Virus, H1N1 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Abzyme Therapeutics LLCAdimmune Corp
Alla Chem LLC
Allergy Therapeutics Plc
Ansun Biopharma Inc
Arizona State University
AVM Biotechnology LLC
Baylor Scott & White Research Institute
BioTherapeutics Inc
Blue Water Biotech Inc
Brandenburg Antiinfektiva GmbH
BunyaVax BV
Butantan Institute
CEL-SCI Corp
Celestial Therapeutics Inc
Changchun Institute of Biological Products Co Ltd
Chicago Biosolutions Inc
CHO Pharma Inc
Chongqing Zhifei Biological Products Co Ltd
Cidara Therapeutics Inc
Cilian AG
Cocrystal Pharma Inc
Codagenix Inc
Collaborations Pharmaceuticals Inc
ContraFect Corp
CSL Ltd
Curevac NV
CytoAgents Inc
Dalian Ya Li-feng Biological Pharmaceutical Co Ltd
Dnarx LLC
Dynamic Entropy Technology LLC
Emory University
ENA Respiratory Pty Ltd
EpiVax Inc
ExpreS2ion Biotech Holding AB
FluGen Inc
Gamma Vaccines Pty Ltd
GSK plc
Helix Biogen Institute
ILiAD Biotechnologies LLC
ImmunityBio Inc
Imutex Ltd
InvVax Inc
Jiangsu Ab&b Bio-tech Co Ltd
Jiangsu Kangrun Biological Technology Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Liaoning Cheng Da Biotechnology Co Ltd
Massachusetts Institute of Technology
Meletios Therapeutics SAS
Microbiotix Inc
Moderna Inc
MVRIX Corp
Mynvax Pvt Ltd
New Amsterdam Sciences Inc
Novavax Inc
NuGenerex Immuno-Oncology Inc
Nykode Therapeutics ASA
Osivax SAS
PeptiDream Inc
Pneumagen Ltd
Recce Pharmaceuticals Ltd
RedHill Biopharma Ltd
Replikins Ltd
SAB Biotherapeutics Inc
Sanofi
Scientific Research Institute for Biological Safety Problems
Serum Institute of India Pvt Ltd
Shanghai Institute of Biological Products Co Ltd
Statera Biopharma Inc
TechnoVax Inc
Texas Tech University Health Sciences Center
The Government Pharmaceutical Organization
The Institute of Vaccines and Medical Biologicals
The National Institute of Allergy and Infectious Diseases
Tiba Biotech LLC
University of Barcelona
University of Edinburgh
University of Hong Kong
University of North Carolina at Chapel Hill
University of Pittsburgh
University of St. Andrews
University of Wisconsin Madison
Vacthera BioTech GmbH
Vaxart Inc
Vaxess Technologies Inc
Veru Inc
Viramatix Sdn Bhd
Viriom Inc
Vironova Medical AB
Vivaldi Biosciences Inc
Wake Forest University
Zhengzhou University
Zosano Pharma Corp